Stemless vs Standard Shoulder Replacement for Joint Dysfunction
Trial Summary
What is the purpose of this trial?
The SMR Stemless Reverse is intended for total, primary shoulder joint replacement by reducing pain and restoring shoulder articular mobility function. This is a prospective, multi-center, randomized, controlled trial to demonstrate non-inferiority of the SMR Stemless Reverse to the SMR Reverse Shoulder System. Patients with joint dysfunction who continue to experience significant symptoms despite an appropriate course of non-operative management are eligible. Patients will be considered enrolled into the study when an ICF has been signed, all inclusion criteria are met and no exclusion criteria are present including intraoperative exclusion criteria, and the patient is randomized into either the SMR Stemless Reverse (investigational) group, the SMR Reverse Shoulder System (control) group or is part of the roll-in population. Enrollment is expected to take approximately 24 months.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you have had corticosteroid injections in the shoulder within the last 3 months, you may not be eligible to participate.
What data supports the effectiveness of the SMR Reverse Shoulder System treatment for joint dysfunction?
Is the SMR Reverse Shoulder System safe for humans?
How does the SMR Stemless Reverse Shoulder System treatment differ from other treatments for shoulder joint dysfunction?
The SMR Stemless Reverse Shoulder System is unique because it uses a stemless design, which can lead to fewer complications related to the shaft, preserve more bone, and make future surgeries easier. This system is modular, allowing for customization to fit the patient's anatomy, and has shown promising results in terms of improved shoulder function and reduced pain.24567
Research Team
Grant Garrigues, MD
Principal Investigator
Rush Orthopedics
Eligibility Criteria
This trial is for adults over 22 years old needing a primary total shoulder replacement due to severe joint issues like rotator cuff tear arthropathy or osteoarthritis. Candidates must have tried non-surgical treatments without relief. Exclusions include obesity (BMI > 40), certain bone and metabolic conditions, recent surgeries on the same or opposite shoulder, and systemic infections.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo total reverse shoulder arthroplasty with either the SMR Stemless Reverse or SMR Reverse Shoulder System
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments of implant loosening and quality of life measures
Treatment Details
Interventions
- SMR Reverse Shoulder System (Joint Replacement)
- SMR Stemless Reverse (Joint Replacement)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Limacorporate S.p.a
Lead Sponsor
NAMSA
Collaborator